BR0009539A - composto, composição farmacêutica, método para tratamento ou prevenção de uma doença ou distúrbio associado com agonismo patogênico, agonismo inverso ou antagonismo do receptor gaba a, uso de um composto, método para localizar receptores gaba a em uma amostra de tecido, método para alterar a atividade transdutora de sinal de receptores gaba a, método para o tratamento ou prevenção de distúrbios psicológicos associados com modulação do complexo receptor gaba a, e, processo para a preparação de um composto - Google Patents

composto, composição farmacêutica, método para tratamento ou prevenção de uma doença ou distúrbio associado com agonismo patogênico, agonismo inverso ou antagonismo do receptor gaba a, uso de um composto, método para localizar receptores gaba a em uma amostra de tecido, método para alterar a atividade transdutora de sinal de receptores gaba a, método para o tratamento ou prevenção de distúrbios psicológicos associados com modulação do complexo receptor gaba a, e, processo para a preparação de um composto

Info

Publication number
BR0009539A
BR0009539A BRPI0009539-7A BR0009539A BR0009539A BR 0009539 A BR0009539 A BR 0009539A BR 0009539 A BR0009539 A BR 0009539A BR 0009539 A BR0009539 A BR 0009539A
Authority
BR
Brazil
Prior art keywords
gaba
compound
receptor
treating
sub
Prior art date
Application number
BRPI0009539-7A
Other languages
English (en)
Inventor
Robert W Desimone
Alan Hutchhison
Kenneth Shaw
Daniel L Rosewater
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of BR0009539A publication Critical patent/BR0009539A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODO PARA TRATAMENTO OU PREVENçãO DE UMA DOENçA OU DISTúRBIO ASSOCIADO COM AGONISMO PATOGêNICO, AGONISMO INVERSO OU ANTAGONISMO DO RECEPTOR GABA~ A~, USO DE UM COMPOSTO, MéTODO PARA LOCALIZAR RECEPTORES GABA~ A~ EM UMA AMOSTRA DE TECIDO, MéTODO PARA ALTERAR A ATIVIDADE TRANSDUTORA DE SINAL DE RECEPTORES GABA~ A~, MéTODO PARA O TRATAMENTO OU PREVENçãO DE DISTúRBIOS PSICOLóGICOS ASSOCIADOS COM MODULAçãO DO COMPLEXO RECEPTOR GABA~ A~, E, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO". São descritos compostos da fórmula (I): ou os sais farmaceuticamente aceitáveis dos mesmos, em que a A, B, C, D, X, R~ 1~, R~ 2~, R~ 3~, R~ 4~, R~ 5~, e R~ 6~ são variáveis definidas aqui, cujos compostos são altamente agonistas ou agonistas inversos para receptores de cérebro GABA~ A~ ou pró-drogas de agonistas, antagonistas ou agonistas inversos para receptores de cérebro GABA~ A~, e são portanto utilizáveis no diagnóstico e tratamento da ansiedade, Sindrome de Down, sono, distúrbios de apreensão e cognitivo, depressão, overdose com drogas de benzodiazepina, e intensificação de memória e atividade.
BRPI0009539-7A 1999-04-02 2000-03-31 composto, composição farmacêutica, método para tratamento ou prevenção de uma doença ou distúrbio associado com agonismo patogênico, agonismo inverso ou antagonismo do receptor gaba a, uso de um composto, método para localizar receptores gaba a em uma amostra de tecido, método para alterar a atividade transdutora de sinal de receptores gaba a, método para o tratamento ou prevenção de distúrbios psicológicos associados com modulação do complexo receptor gaba a, e, processo para a preparação de um composto BR0009539A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12752699P 1999-04-02 1999-04-02
US28535799A 1999-04-02 1999-04-02
PCT/US2000/008610 WO2000059905A1 (en) 1999-04-02 2000-03-31 ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS

Publications (1)

Publication Number Publication Date
BR0009539A true BR0009539A (pt) 2006-06-06

Family

ID=26825721

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0009539-7A BR0009539A (pt) 1999-04-02 2000-03-31 composto, composição farmacêutica, método para tratamento ou prevenção de uma doença ou distúrbio associado com agonismo patogênico, agonismo inverso ou antagonismo do receptor gaba a, uso de um composto, método para localizar receptores gaba a em uma amostra de tecido, método para alterar a atividade transdutora de sinal de receptores gaba a, método para o tratamento ou prevenção de distúrbios psicológicos associados com modulação do complexo receptor gaba a, e, processo para a preparação de um composto

Country Status (11)

Country Link
US (1) US7348326B2 (pt)
EP (1) EP1165557B1 (pt)
JP (1) JP2002541151A (pt)
AT (1) ATE277927T1 (pt)
AU (1) AU4058000A (pt)
BR (1) BR0009539A (pt)
CA (1) CA2369557A1 (pt)
DE (1) DE60014339T8 (pt)
ES (1) ES2226812T3 (pt)
MX (1) MXPA01009949A (pt)
WO (1) WO2000059905A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4055300A (en) * 1999-04-02 2000-10-23 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of Bradykinin B2 receptors
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
WO2002028839A1 (en) * 2000-10-06 2002-04-11 Neurogen Corporation Benzimidazole and indole derivatives as crf receptor modulators
PA8535601A1 (es) * 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
JP2005526709A (ja) 2002-01-10 2005-09-08 ニューロジェン・コーポレーション メラニン凝集ホルモン受容体リガンド：置換ベンゾイミダゾールアナログ
PE20040804A1 (es) * 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
US7351826B2 (en) 2003-02-19 2008-04-01 Neurogen Corporation Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds
ES2222813B1 (es) * 2003-07-24 2005-12-16 Ferrer Internacional, S.A. N-(3-(3-sustituidas-pirazolo(1,5-a)pirimidin-7-il)-fenil)-sulfonamidas y composiciones y metodos relacionados.
ATE350382T1 (de) * 2003-07-25 2007-01-15 Neurogen Corp Imidazopyrimidine und triazolopyrimidine: benzodiazepinrezeptorliganden
CN101675928A (zh) * 2003-11-14 2010-03-24 沃泰克斯药物股份有限公司 可用作atp-结合弹夹转运蛋白调控剂的噻唑和噁唑
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
US8815881B2 (en) * 2010-08-09 2014-08-26 Hoffmann-La Roche Inc. 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds
MA34591B1 (fr) 2010-10-06 2013-10-02 Glaxosmithkline Llc Dérivés de benzimidazole utilisés comme inhibiteurs de pi3 kinase
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
AR095883A1 (es) * 2013-04-18 2015-11-18 Astellas Pharma Inc Compuestos de acetamida heterocíclica
JP2023512038A (ja) * 2020-01-29 2023-03-23 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527819A (en) * 1991-09-06 1996-06-18 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
AU675484B2 (en) * 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation
NZ290008A (en) * 1994-06-29 1998-08-26 Smithkline Beecham Corp Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle
JP3342874B2 (ja) * 1995-04-21 2002-11-11 ニューロサーチ、アクティーゼルスカブ ベンズイミダゾール化合物、およびｇａｂａａレセプター複合体モジュレーターとしてのその使用
AU1354097A (en) * 1995-12-29 1997-07-28 Smithkline Beecham Corporation Vitronectin receptor antagonists
CN1115336C (zh) * 1996-10-21 2003-07-23 神经研究公司 1－苯基－苯并咪唑类化合物及其作为baga－a受体调节剂的用途
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors

Also Published As

Publication number Publication date
MXPA01009949A (es) 2003-07-14
US7348326B2 (en) 2008-03-25
WO2000059905A1 (en) 2000-10-12
DE60014339T8 (de) 2006-04-27
EP1165557B1 (en) 2004-09-29
DE60014339T2 (de) 2006-02-09
AU4058000A (en) 2000-10-23
JP2002541151A (ja) 2002-12-03
ATE277927T1 (de) 2004-10-15
CA2369557A1 (en) 2000-10-12
DE60014339D1 (de) 2004-11-04
ES2226812T3 (es) 2005-04-01
US20060160842A1 (en) 2006-07-20
EP1165557A1 (en) 2002-01-02

Similar Documents

Publication Publication Date Title
BR0009539A (pt) composto, composição farmacêutica, método para tratamento ou prevenção de uma doença ou distúrbio associado com agonismo patogênico, agonismo inverso ou antagonismo do receptor gaba a, uso de um composto, método para localizar receptores gaba a em uma amostra de tecido, método para alterar a atividade transdutora de sinal de receptores gaba a, método para o tratamento ou prevenção de distúrbios psicológicos associados com modulação do complexo receptor gaba a, e, processo para a preparação de um composto
BR0010308A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma doença ou distúrbio associados com o agonismo patogênico, agonismo inverso ou antagonismo do receptor de gabaa, para localizar receptores de gabaa em uma amostra de tecido, para inibir a ligação de um composto de benzodiazepina a um receptor de gabaa e para alterar a atividade da transdução de sinal dos receptores de gabaa, e, composição farmacêutica embalada
MXPA03001344A (es) Derivados de piridina 2,4-substituidos.
Lagos et al. Effects of the D3 preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats
DK0555391T3 (da) Visse imidazoquinoxaliner; en ny klasse GABA-receptorligander i hjernen
WO2002000623A3 (en) Aryl fused substituted 4-oxy-pyridines
CA2175204A1 (en) Certain Fused Pyrrolecarboxanilides; a New Class of GABA Brain Receptor Ligands
CA2091986A1 (en) Certain cycloalkyl and azacycloalkyl pyrrolopyrimidines; a new class of gaba brain receptor ligands
Heppelmann et al. Effects of acetylsalicylic acid and indomethacin on single groups III and IV sensory units from acutely inflamed joints
CA2301599A1 (en) Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
ATE296290T1 (de) Substituierte cycloalkyl-4-oxonicotinische karboxamide; gaba gehirn-rezeptorligande
BR0013664A (pt) Composto, uso de um composto, composição farmacêutica, e, métodos para o tratamento de uma doença ou distúrbio associado com agonismo patogênico, agonismo invertido ou antagonismo do receptor de gabaa, para localizar os receptores de gabaa, para inibir a ligação de um composto de benzodiazepina a um receptor de gabaa, e para alterar a atividade de transdução de sinal de receptores gabaa
BRPI0413584A (pt) composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de doenças e para tratamento de um distúrbio no sistema nervoso central
Ikeda‐Sagara et al. Induction of prolonged, continuous slow‐wave sleep by blocking cerebral H1 histamine receptors in rats
BR0307504A (pt) Composto ou sal farmaceuticamente aceitável, composição farmacêutica, métodos tratar doenças, para potencializar um efeito terapêutico de um agente para o snc, para melhorar a memória de curto prazo em um paciente, para determinar a presença ou ausência de receptores gabaa em uma amostra, e para alterar a atividade transdutora de sinal do receptor gabaa, embalagem, e, uso de um composto ou sal
Kantor et al. Despite similar anxiolytic potential, the 5-hydroxytryptamine 2C receptor antagonist SB-242084 [6-chloro-5-methyl-1-[2-(2-methylpyrid-3-yloxy)-pyrid-5-yl carbamoyl] indoline] and chlordiazepoxide produced differential effects on electroencephalogram power spectra
BR0208241A (pt) Composto, composições farmacêutica métodos para o tratamento de ansiedade, depressão, um distúrbio do sono, distúrbio de déficit de atenção, ou demência de alzheimer, para aumentar a potência de um efeito terapêutico de um agente do cns, para determinar a presença ou ausência de receptor de gabaa em uma amostra, e para alterar a atividade de transdução de sinal de receptor de gabaa, e, uso de um composto
WO2002066468A3 (en) Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands
CA2223936A1 (en) Novel substituted aryl and cycloalkyl imidazolones; a new class of gaba brain receptor ligands
DE69926378D1 (de) Oxo-pyridoimidazol-carboxamide: gaba-rezeptor-liganden im gehirn
DK1192161T3 (da) Chromeno[4,3,2-de]isoquinoliner som kraftige dopaminreceptorligander
Wada et al. Action of the selective 5‐HT4 receptor antagonist SB 204070A in the rat kindling model of epilepsy
MY107732A (en) Certain imidazoquinoxalines; a new class of gaba brain receptor ligands.
EP0621781A1 (en) Use of 3-arylindole and 3-arylindazole derivatives for the treatment of psychoses
Benoit et al. Brain imaging in the diagnosis of Alzheimer's disease

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10(VIII), 13 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.